Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation

BACKGROUND: The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients. Resistant T315I clone may be present prior to initiating dasatinib, which could expand under selective pressures during treatment. However,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Takahashi, Naoto, Miura, Masatomo, Scott, Stuart A, Niioka, Takenori, Sawada, Kenichi
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3409074/
https://ncbi.nlm.nih.gov/pubmed/22587422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-5-23
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars